Dicerna – Patient Worthy

source: pixabay.com

Alpha-1 Antitrypsin Deficiency Treatment Receives Orphan Drug Designation

Post author:Jessica Lynn
Post published:March 31, 2020
Post category:Alpha-1 Antitrypsin Deficiency Hepatocellular Carcinoma

In June 2019, Dicerna Pharmaceuticals submitted a clinical trial application for their DCR-A1AT therapy and expects to treat the first patient with A1AD-related liver disease near the end of…

CLICK HERE TO SHARE YOUR STORY!

We believe rare disease patients are people, not a diagnosis. Through education, awareness and some humor, we help patients, caregivers and support persons by providing relevant and often inspirational news and stories.

Our goals are to share stories, cultivate strong community, provide the latest medical findings, connect people and pioneer production of patient worthy information. Help us attain these goals by telling us a little bit about yourself!

Let’s Work Together!

Keep Up to Date

Learn More